Bringing together academic and private industries in pursuit of biomedical discovery leverages the best of both institutions to advance human health and benefit a large population. Though these partnerships begin with a shared vision, different interests between the two groups can jeopardize their work, said Dr. Til Stürmer, Nancy A. Dreyer Distinguished Professor and chair of the University of North Carolina-Chapel Hill Gillings School of Global Public Health’s department of epidemiology.
Dr. Stürmer co-authored a set of guiding principles and considerations that public-private partners can use in pharmacoepidemiological research to create scientifically sound research studies that also acknowledge the different interests between the two groups. “Principles and Considerations for Effective Academia–Industry Collaboration in Pharmacoepidemiology” was published in Pharmacoepidemiology and Drug Safety.
The report includes five principles that, when addressed at the outset of the project and confirmed in an official agreement, can help avoid roadblocks to meaningful pharmacoepidemiological research and outcomes:
Incorporating these principles into these agreements creates a framework that can be embedded into existing agreements or used to create new ones, said Dr. Stürmer. The document has been endorsed by the International Society for Pharmacoepidemiology (ISPE).
“The authors and ISPE invite discussion on this document and hope that it will serve as guidance for academia-industry collaborations in pharmacoepidemiology and beyond,” Dr. Stürmer said.